-
Mashup Score: 15Paper: Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Researc h: Plasma Cell Disorders: Poster I Hematology Disease Topics & Pathways: Chimeric Antigen Receptor (CAR)-T Cell Therapies, Biological therapies, Treatment Considerations Bhavesh Mohan Lal, MD 1, Toshali Pandey 2 *, Marah Alzubi 3 *, Jawad Alrawabdeh 3 *, John D Shaughnessy, Jr, PhD 4 *, Fenghuang Zhan, MD 5, Eric Siegel 6 *, Carolina Schinke, MD 5, Sharmilan Thanendrarajan, MD 7, Maurizio Zangari, MD 5, Frits van Rhee, MD, PhD 5 and Samer
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 112Volume 2024 Issue 1 | Hematology, ASH Education Program | American Society of Hematology - 3 month(s) ago
Hematology, ASH Education Program | 2024 | 1 | November 2024
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
One of the best resources for trainees and attendees #ASH24 @ASH_hematology #mmsm @HemOncFellows Hematology Education Program 2024 Access: https://t.co/HtSMiawC3S Many review articles with updates across all hematological disorders https://t.co/n58itRWVdn
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events Elena Zamagni, MD 1 *, Tobias Silzle, MD 2 *, Ivan Špička 3 *, Sabrin Tahri, MD 4 *, Sarah Lonergan 4 *, Inger S. Nijhof, MD, PhD 5 *, Antonietta Pia Falcone,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 1️⃣0️⃣ Majestec-4/EMN30 Trial ➡️ https://t.co/gAOFjnxR4S ✅Multiple cohorts comparing Tec alone, Tec-Len vs Len alone post ASCT- time limited maintenance in all pts Will be interesting to see if intensifying maintenance for 2 yrs will improve efficacy/safety https://t.co/KclSGJQAU1
-
-
Mashup Score: 111Volume 2024 Issue 1 | Hematology, ASH Education Program | American Society of Hematology - 3 month(s) ago
Hematology, ASH Education Program | 2024 | 1 | November 2024
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
One of the best resources for trainees and attendees #ASH24 @ASH_hematology #mmsm @HemOncFellows Hematology Education Program 2024 Access: https://t.co/HtSMiawC3S Many review articles with updates across all hematological disorders https://t.co/n58itRWVdn
-
-
Mashup Score: 17
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP 1, Binod Dhakal, MBBS 2, Gurbakhash Kaur, MD, MA 3,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 7️⃣ IMMagine-1 Trial-Anitocabtagene autoleucel (CART-ddBCMA) ➡️ https://t.co/t8Nb52lHpi ✅n=58 pts, median FU:10.3 mo ✅ORR:95%, PFS/OS: NR 🛑5% death related to AEs Early follow up- need to follow up for AEs for longer period of time https://t.co/IrAOMgzwpy
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human Meletios-Athanasios Dimopoulos 1, Peter M. Voorhees, MD 2, Fredrik Schjesvold, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 3️⃣ AQUILA study ➡️ https://t.co/cBxHkGczl9 ✅ Dara vs active monitoring in smoldering myeloma ✅ n=390, median F/U: 5.5 yrs ✅ORR in 2/3 of pts 🛑one third of Dara pts received second line ttt Data on progression events will be imp https://t.co/jlYZOAaqNv
-
-
Mashup Score: 33Your Social Media Guide to #ASH24 | ASH News Daily | American Society of Hematology - 3 month(s) ago
Take advantage of these helpful tips and tricks to help enhance your meeting experience through social media during #ASH24. For up-to-the-minute ASH annual meeting content, follow the Society’s official social media accounts: X (formerly Twitter), Instagram, LinkedIn, Facebook, and YouTube. ASH will share important updates and reminders, attendee photos and posts, and links to content you won’t want to miss, including ASH News Daily articles and clips from ASH News TV. Catch the latest in hematology in
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Check: Your Social Media Guide to #ASH24 @ASH_hematology 👇 ➡️https://t.co/ntwMjhkaXh Many excellent handles to follow along with ASH News Daily (@JuliPerezBot @JoselleCookMD et al) https://t.co/LsRGVivmgV
-
-
Mashup Score: 33Your Social Media Guide to #ASH24 | ASH News Daily | American Society of Hematology - 3 month(s) ago
Take advantage of these helpful tips and tricks to help enhance your meeting experience through social media during #ASH24. For up-to-the-minute ASH annual meeting content, follow the Society’s official social media accounts: X (formerly Twitter), Instagram, LinkedIn, Facebook, and YouTube. ASH will share important updates and reminders, attendee photos and posts, and links to content you won’t want to miss, including ASH News Daily articles and clips from ASH News TV. Catch the latest in hematology in
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Check: Your Social Media Guide to #ASH24 @ASH_hematology 👇 ➡️https://t.co/ntwMjhkaXh Many excellent handles to follow along with ASH News Daily (@JuliPerezBot @JoselleCookMD et al) https://t.co/LsRGVivmgV
-
-
Mashup Score: 15
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma Hematology Disease Topics & Pathways: Bispecific Antibody Therapy, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Joshua Richter, MD 1, Sheeba K. Thomas, MD 2, Amrita Y Krishnan, MD, FACP 3, Jacob P. Laubach 4 *, Adam D. Cohen, MD 5, Suzanne Trudel, MD, MSc 6, Luciano J. Costa, MD, PhD
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 6️⃣ Cevostamab ➡️ https://t.co/jf1tpdUOks ✅n=167 pts ✅Median FU ~1 yr ✅ORR (43%) lower than other BsAbs and with prior BCMA was lower at 30% ✅DOR: 10.4 mo 🛑ICANS G2-3 was seen in 7.2% of pts https://t.co/Rf5eB10WNp
-
-
Mashup Score: 17
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP 1, Binod Dhakal, MBBS 2, Gurbakhash Kaur, MD, MA 3,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 7️⃣ IMMagine-1 Trial-Anitocabtagene autoleucel (CART-ddBCMA) ➡️ https://t.co/t8Nb52lHpi ✅n=58 pts, median FU:10.3 mo ✅ORR:95%, PFS/OS: NR 🛑5% death related to AEs Early follow up- need to follow up for AEs for longer period of time https://t.co/IrAOMgzwpy
-
#ASH24 #mmsm @ASH_hematology Check @Dr_Bhavesh_M @UAMSMyeloma @UAMSintmedicine Our work with abstract achievement award #ASHKudos ➡️ https://t.co/iedzTMxuDp Come check it out poster 2405 and get to see outcomes of CAR-T per intention to treat for those who got CAR-T and… https://t.co/Kw5AXyeR9W https://t.co/p2oqzvqb6M